Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025

He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardiomyopathy patients. Plus, learnings from a competitor's data in non-obstructive HCM, and the status of the company's regulatory review.